Executive Actions Tracker

This executive order establishes "Gold Standard Childhood Vaccine Recommendations" organizing childhood immunizations into three categories (recommended for all children, recommended for high-risk groups, and based on shared clinical decision-making) and directs all agencies to advance them. It directs the Secretary of HHS, through the HHS Task Force on Safer Childhood Vaccines, to present plans to the President within 90 days on offering single-disease vaccines starting with MMR, adjusting the federal vaccine schedule, developing alternative adjuvants, and improving safety monitoring. It also directs the Attorney General to further legal actions challenging state laws that conflict with obligations related to parental authority, religious freedom, disability accommodations, and equal protection, and directs the Departments of Justice, Education, and HHS to ensure their contractors and grantees, including states and localities, provide religious and medical exemptions from immunization requirements where required by federal law.

Clients in Life Sciences · Healthcare

This executive order directs the Commissioner of Food and Drugs to grant Commissioner's National Priority Vouchers to eligible psychedelic drugs with Breakthrough Therapy designation and directs the FDA and Drug Enforcement Administration to establish a pathway for patient access to psychedelic drugs, including ibogaine compounds, under the Right to Try Act. It directs the Secretary of Health and Human Services to allocate at least $50 million through the Advanced Research Projects Agency for Health to partner with state programs advancing psychedelic drugs for serious mental illness, directs HHS, FDA, and the Department of Veterans Affairs to collaborate on clinical trials and sign data-sharing memoranda, and directs the Attorney General, in consultation with HHS, to review Schedule I products that complete Phase 3 trials for potential rescheduling.

Clients in Life Sciences · Healthcare

This EO directs the expedited rescheduling of marijuana from Schedule I to Schedule III, acknowledging its accepted medical use and reduced abuse potential. It further calls for a regulatory framework and improved research on both medical marijuana and hemp-derived CBD products, including clear guidance on THC limits and accurate product labeling. The order aims to close gaps in medical knowledge so patients and providers may access safe, effective, and well-informed treatment options.

Clients in Cannabis · Healthcare · Life Sciences

This EO directs federal agencies to harness artificial intelligence to accelerate pediatric cancer research, improve data sharing, and enhance clinical care, prioritizing innovation, investment, and interoperability in health data. It establishes a coordinated effort to use AI-enabled solutions for better diagnostics, treatments, and prevention, while ensuring patient privacy and encouraging public and private sector engagement.

Clients in Healthcare · Life Sciences · AI, Robotics and Quantum

This Executive Order seeks to align U.S. prescription drug prices with those in comparably developed countries by implementing a “most-favored-nation” pricing strategy. It directs the Secretary of Health and Human Services to communicate price targets to pharmaceutical manufacturers within 30 days and to facilitate direct-to-consumer programs offering drugs at the most-favored-nation price. If significant progress is not made, the order authorizes additional actions, including proposed rulemaking, importation certifications, antitrust enforcement, export controls, and potential FDA regulatory reviews. The order also calls on the Department of Commerce and USTR to address international pricing practices that contribute to disproportionately high drug costs for American consumers.

Clients in Life Sciences · Healthcare

This Executive Order aims to strengthen the U.S. pharmaceutical supply chain by removing regulatory barriers to domestic manufacturing. It directs the FDA, EPA, and U.S. Army Corps of Engineers to review and streamline applicable regulations and guidance within 180 days to improve the timeliness and predictability of agency review processes. The order also calls for enhanced inspections of foreign pharmaceutical facilities, increased transparency on inspection activities, and centralized coordination of environmental permits for new manufacturing sites. The policy goal is to create a more resilient, competitive, and secure domestic pharmaceutical manufacturing base.

Clients in Life Sciences · Healthcare · Environmental

This EO directs all executive departments and agencies that address health or healthcare to focus on reversing chronic disease, including the following actions: all federally funded health research should use transparency and open-source data and eliminate conflicts of interest; NIH and other federal health research initiatives should prioritize research on chronic illness; agencies should work with farmers to ensure US food is healthy, abundant, and affordable; and agencies should ensure availability of expanded treatment options and flexible insurance coverage for lifestyle changes/disease prevention. Further, the Make America Healthy Again Commission is established with the initial mission to advise the President how to address childhood chronic disease (reports due in 100 days and 180 days).

Clients in Healthcare · Life Sciences · Food and Beverage